Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

PubMed  Google Scholar 

Cheng KC, Lin WY, Liu CS, Lin CC, Lai HC, Lai SW. Association of different types of liver disease with demographic and clinical factors. Biomedicine (Taipei). 2016;6(3):16.

PubMed  Google Scholar 

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17.

PubMed  Google Scholar 

Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471–7.

CAS  PubMed  Google Scholar 

Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment strategies for hepatocellular carcinoma a multidisciplinary approach. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20061465.

Article  PubMed  PubMed Central  Google Scholar 

Suresh D, Srinivas AN, Prashant A, Harikumar KB, Kumar DP. Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clin Exp Med. 2023;23(6):1901–16.

PubMed  Google Scholar 

Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019. https://doi.org/10.1053/j.gastro.2018.08.065.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

PubMed  Google Scholar 

Borish LC, Steinke JW. 2 cytokines and chemokines. J Allergy Clin Immunol. 2003. https://doi.org/10.1067/mai.2003.108.

Article  PubMed  Google Scholar 

Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: from clinical significance to quantification. Adv Sci (Weinh). 2021;8(15): e2004433.

PubMed  Google Scholar 

Sheu BC, Chang WC, Cheng CY, Lin HH, Chang DY, Huang SC. Cytokine regulation networks in the cancer microenvironment. Front Biosci. 2008;13:6255–68.

CAS  PubMed  Google Scholar 

Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The role of cytokines in the different stages of hepatocellular carcinoma. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13194876.

Article  PubMed  Google Scholar 

Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother. 2001;55(9–10):543–7.

CAS  PubMed  Google Scholar 

Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.

CAS  PubMed  Google Scholar 

Chen H, Tang C, Tan C, Wu F, Li Z, Ji W, Lu L, Xu C, Shen Z, Huang Y. IL-2 Modulates TAMs derived exosomal MiRNAs to ameliorate hepatocellular carcinoma development and progression. J Oncol. 2022;2022:3445350.

PubMed  PubMed Central  Google Scholar 

Zhou H, Huang H, Shi J, Zhao Y, Dong Q, Jia H, Liu Y, Ye Q, Sun H, Zhu X, Fu L, Guo K, Gao D, Sun J, Yan Z, Ren N, Tang Z, Qin L. Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection. Gut. 2010;59(12):1699–708.

PubMed  Google Scholar 

Ren X, Zhou Y, Luo Y, Wang C, Pan A, Ju Y, Sun H, Lin Z, Hu B, Sun G, Zhu W, Hong L. IL-6 promotes hepatocellular carcinoma invasion by releasing exosomal miR-133a-3p. Gastroenterol Res Pract. 2022;2022:4589163.

PubMed  PubMed Central  Google Scholar 

Zhu Y, Gu J, Lu Y, Tao Q, Cao X, Zhu Y, Yang MQ, Liang X. IL-6 released from hepatic stellate cells promotes glycolysis and migration of HCC through the JAK1/vWF/TGFB1 Axis. J Hepatocell Carcinoma. 2024;11:1295–310.

PubMed  PubMed Central  Google Scholar 

Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60(3):686–93.

CAS  PubMed  Google Scholar 

Shao YY, Lin H, Li YS, Lee YH, Chen HM, Cheng AL, Hsu CH. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2017;47(10):949–53.

PubMed  Google Scholar 

Ocal O, Schutte K, Kupcinskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klumpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol. 2022;148(2):475–85.

PubMed  Google Scholar 

Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Matoya S, Miyaki T, Kimura Y, Kusakabe A, Narahara S, Tokunaga T, Nagaoka K, Murakami S, Inoue T, Kuroyanagi K, Kawamura H, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis. J Gastroenterol Hepatol. 2024;39(10):2158–68.

CAS  PubMed  Google Scholar 

Hu Y, Zhou Y, Du S, Zhu W, Chen Y, Zeng Z. Effect of serum interleukin-6 concentration on the prognosis after radiotherapy for patients with hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2024;2024:4696097.

PubMed  PubMed Central  Google Scholar 

Sun F, Wang J, Sun Q, Li F, Gao H, Xu L, Zhang J, Sun X, Tian Y, Zhao Q, Shen H, Zhang K, Liu J. Interleukin-8 promotes integrin beta3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):449.

PubMed  PubMed Central  Google Scholar 

Xue JC, Zhou HY, Yu LS, Wu YY. Effect of IL-8 on hepatocellular carcinoma-associated metastasis by targeting MMP9 in mice. Transl Cancer Res. 2022;11(7):2050–60.

CAS  PubMed  PubMed Central  Google Scholar 

Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, Zhao YM, Xiao YS, Sun QM, Ding ZB, Fan J. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol. 2015;46(2):587–96.

CAS  PubMed  Google Scholar 

Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, Yu WC, Fan ST. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res. 2003;9(16):5996–6001.

CAS  PubMed  Google Scholar 

Welling TH, Fu S, Wan S, Zou W, Marrero JA. Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest. 2012;30(10):689–97.

CAS  PubMed  Google Scholar 

Kim SS, Cho HJ, Won JH, Bae JI, Kang DR, Lee JD, Shin SJ, Lee KM, Yoo BM, Kim JK, Lee JH, Ahn SJ, Park JH, Cho SW, Cheong JY. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. Cytokine. 2015;76(2):449–57.

CAS  PubMed  Google Scholar 

Zhang S, Gan X, Qiu J, Ju Z, Gao J, Zhou J, Shi C, Zhu Y, Li Z. IL-10 derived from Hepatocarcinoma cells improves human induced regulatory T cells function via JAK1/STAT5 pathway in tumor microenvironment. Mol Immunol. 2021;133:163–72.

CAS  PubMed  Google Scholar 

Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg. 2000;231(4):552–8.

CAS  PubMed  PubMed Central  Google Scholar 

Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012;118(16):3984–92.

CAS  PubMed  Google Scholar 

Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF, Guan XY. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS ONE. 2011;6(7): e21816.

CAS  PubMed  PubMed Central  Google Scholar 

Xu QG, Yu J, Guo XG, Hou GJ, Yuan SX, Yang Y, Yang Y, Liu H, Pan ZY, Yang F, Gu FM, Zhou WP. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma. Mol Oncol. 2018;12(6):936–52.

CAS  PubMed  PubMed Central  Google Scholar 

Cho HJ, Kim SS, Nam JS, Oh MJ, Kang DR, Kim JK, Lee JH, Kim B, Yang MJ, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW, Cheong JY. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. Cytokine. 2017;95:118–25.

CAS  PubMed  Google Scholar